Product Description
Colesevelam is used in adults along with diet, weight loss, and exercise to reduce the amount of cholesterol and certain fatty substances in the blood alone or in combination with other cholesterol-lowering medications known as HMG-CoA reductase inhibitors (statins). Colesevelam is also used alone or in combination with HMG-CoA reductase inhibitors in certain boys and in girls, ages 10 to 17, with familial heterozygous hypercholesterolemia (an inherited condition in which cholesterol cannot be removed from the body normally) to decrease the amount of cholesterol and other fatty substances in the blood. Colesevelam is also used along with diet and exercise to control blood sugar levels in adults with type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood). Colesevelam is in a class of medications called bile acid sequestrants. It works by binding bile acids in your intestines to form a product that is removed from the body (Sourced from: https://medlineplus.gov/druginfo/meds/a699050.html)
Mechanisms of Action: SGLT2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Belgium | Brazil | Canada | Croatia | Cyprus | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | India | Ireland | Latvia | Lithuania | Mexico | Netherlands | Norway | Poland | Portugal | Slovakia | Slovenia | Spain | Sweden | Taiwan | Turkey | United Kingdom | United States
Approved Indications: Hyperlipidemia | Type 1 Diabetes | Acidosis | Diabetic Ketoacidosis | Dyslipidemia | General Diabetes | Hypercholesterolemia | Type 2 Diabetes | Hyperlipidemia | Type 1 Diabetes | Acidosis | Diabetic Ketoacidosis | Dyslipidemia | General Diabetes | Hypercholesterolemia | Type 2 Diabetes | Type 1 Diabetes | Acidosis | Diabetic Ketoacidosis | Dyslipidemia | General Diabetes | Hypercholesterolemia | Type 2 Diabetes
Known Adverse Events: Dyspepsia | Constipation | Fecal Impaction | Pancreatitis | Hypertriglyceridemia | Hypoglycemia
Company: Cosette Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: Daiichi Sankyo
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|